Abstract: A battery pack is provided. The battery pack includes: a plurality of battery cells, each of which includes a shell, a battery core, and a plurality of terminal posts. An accommodating space is defined inside the shell. The battery core is disposed in the accommodating space. The shell at least includes a first surface and a second surface. The plurality of terminal posts are disposed on the battery core and extend out of the shell from the first surface. The battery pack further includes an electrical connecting member, which is disposed opposite each of two adjacent first surfaces and is electrically connected to each of two adjacent terminal posts, so as to conduct two adjacent battery cells. The battery pack further includes a heat transfer member, which can transfer heat from the electrical connecting member to the second surface.

Abstract: Disclosed are an instant dissolving device by mass transfer and stretching with a cleaning structure and a dissolving method thereof. The dissolving device consists of a liquid inlet, a stretching repetition unit and a mass transfer unit, the stretching unit is sequentially composed of an upper fixed fluted disc, a movable fluted disc and a lower fixed fluted disc all with a plurality of through holes, and the upper fixed fluted disc and the lower fixed fluted disc are fixed to the dissolving device housing; the polymer gel solution is formed into a “uniform” solution after passing through the mass transfer unit. The dissolving device in the present invention is easy to install, and achieves instant dissolution of the polymers and improves the dissolution efficiency through the joint action of forced stretching and mass transfer by high gravity.

Abstract: Disclosed are an instant dissolving device by mass transfer and stretching with a cleaning structure and a dissolving method thereof. The dissolving device consists of a liquid inlet, a stretching repetition unit and a mass transfer unit, the stretching unit is sequentially composed of an upper fixed fluted disc, a movable fluted disc and a lower fixed fluted disc all with a plurality of through holes, and the upper fixed fluted disc and the lower fixed fluted disc are fixed to the dissolving device housing; the polymer gel solution is formed into a “uniform” solution after passing through the mass transfer unit. The dissolving device in the present invention is easy to install, and achieves instant dissolution of the polymers and improves the dissolution efficiency through the joint action of forced stretching and mass transfer by high gravity.

Abstract: The invention relates to a guide RNA (gRNA) comprising a guide sequence capable of targeting a Cas9 protein to a target sequence in an ICP6 gene of type 1-herpes simplex virus (HSV-1) to provide a specific cleavage event, wherein the target sequence comprises a GATC insertion as compared to a wild-type HSV-1. The invention also relates to a HSV-1 gene-editing system and a gene-editing method for generating a desired recombinant HSV-1 by using said gRNA.

Abstract: The present disclosure provides systems and methods for imaging-guided monitoring and modeling of retinal vascular occlusive conditions. An example integrated optical coherence tomography (OCT) and scanning laser ophthalmoscope (SLO) apparatus includes an OCT subsystem to acquire baseline OCT and OCT angiography (OCTA) volumes of a subject without dye before occlusion and subsequent OCT and OCTA volumes of the subject with dye after occlusion. The example apparatus includes an SLO subsystem including a laser controlled to adjust a laser to form a vascular occlusion at a location on a target vessel of the subject. The example apparatus includes a processor to process the OCT and OCTA volumes and feedback from the OCT subsystem and the SLO subsystem to determine a change in three-dimensional vasculature from before the vascular occlusion to after the vascular occlusion.

Abstract: Systems and methods to measure blood flow using optical coherence tomography are disclosed. An example method includes: performing scanning of a target with beam(s) of incident low coherence radiation, wherein the low coherence radiation is selected from one or more regions of the electromagnetic spectrum based on the target selected; acquiring spectroscopic information from scanning signals generated by the interaction of the incident low coherence radiation and the target; generating image signal data for the target from the scanning signals; processing the image signal data by selecting electro-magnetic property(-ies) related to the modulation of the low coherence radiation by variation of relative permittivity and conductivity of the target; performing a multivariate comparison of the selected electro-magnetic properties related to the modulation of the low coherence radiation by variation of relative permittivity and conductivity of the target; and quantifying motion property(-ies) of the target.

Abstract: The present disclosure provides systems and methods for imaging-guided monitoring and modeling of retinal vascular occlusive conditions. An example integrated optical coherence tomography (OCT) and scanning laser ophthalmoscope (SLO) apparatus includes an OCT subsystem to acquire baseline OCT and OCT angiography (OCTA) volumes of a subject without dye before occlusion and subsequent OCT and OCTA volumes of the subject with dye after occlusion. The example apparatus includes an SLO subsystem including a laser controlled to adjust a laser to form a vascular occlusion at a location on a target vessel of the subject. The example apparatus includes a processor to process the OCT and OCTA volumes and feedback from the OCT subsystem and the SLO subsystem to determine a change in three-dimensional vasculature from before the vascular occlusion to after the vascular occlusion.

Abstract: The invention provides packaged pharmaceutical preparations of Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula where the variables are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

Abstract: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations. This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).

Abstract: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations. This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).

Abstract: Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one tbiol compound with at least one thiol-reactive compound.

Abstract: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations. This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).

Abstract: The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula 1

Abstract: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors, preferably human C5a receptors, Preferred compounds of the invention possess one or more, and preferably two or more, three or more, four or more, or all of the following properties in that they are; 1) multi-aryl in structure (having a plurality of un-fused or fused aryl groups), 2) heteroaryl in structure, 3) orally available in vivo (such that a sub-lethal or preferably a pharmaceutically acceptable oral dose can provide a detectable in vitro effect such as a reduction of C5a-induced neutropenia), 4) comprised of fewer than four, preferably fewer than three, or fewer than two, or no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar concentrations and preferably at

Abstract: Disclosed are compounds of the formula: 1

Abstract: Certain aralkyl diazabicycloalkyl compounds are disclosed for treatment of CNS disorders, such as cerebral ischemia, psychosis, and convulsions.

Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable salts thereof wherein: R1, R2, and R3 are as defined herein; R6 is hydrogen or C1-C6 alkyl; and Q represents a substituted azacycloalkylalkyl group, which compounds are useful in treating psychotic disorders such as schizophrenia and other central nervous system diseases.